The Pharmaceutical Triple Aim
Pharmaceutical companies can generate up to a 29% increase in annual revenue just by addressing medication non-adherence. Download this new investigative report of 21 top pharmaceutical companies.
The Pharmaceutical Triple Aim
Higher Medication Adherence
- Increases Revenue and EPS for Pharma
- Improves Patient Outcomes
- Lowers Healthcare Costs
The numbers in HealthPrize’s newest investigative report tell the story: higher adherence can have a significant impact on pharma’s earnings-per-share (EPS) growth – up to 45% for one company – and it can do so relatively quickly.
Find out how your company ranked: get the report →
Adherence, in stark contrast to other revenue-generating options that are available to pharmaceutical companies, like raising prices, is the only approach that meets the pharmaceutical triple aim of increased revenue at higher margins, improved patient outcomes, and lower overall healthcare costs.
Get the report to find out the adherence revenue potential for AbbVie, AstraZeneca, Biogen, Gilead, GSK, Novo Nordisk, Shire and 14 other top pharmaceutical companies.
HealthPrize simplifies and optimizes the development of branded adherence programs to engage, educate and motivate patients to take their medications as prescribed. Request a demo.